Hypermethylation in these cancers leads to epigenetic silencing of genes including CDKN2A, MGMT and CHFR. MGMT methylation increases the response to temozolomide treatment [31], and methylation of CHFR sensitizes tumors to dodetaxel and paclitaxel [32], as shown by experimental assays with esophageal cell lines. The gene discussed is CDKN2A; the disease is cancer.